Death of the Founder of Abcourt
ROUYN-NORANDA, Quebec, June 05, 2023 (GLOBE NEWSWIRE) -- Abcourt Mines Inc. (“Abcourt” or the “Corporation”) (TSX Venture: ABI) regrets to announce the death of the founder of Abcourt, Renaud Hinse. Mr. Hinse created Abcourt in 1979 and served as president and chief executive officer until April 2022. He was still a director of the Corporation at the time of his death, last Friday.
Throughout these years, Mr. Hinse has been entirely dedicated to the Corporation, putting to good use his professional qualifications as a mining engineer, his vast experience in the mining field in which he has worked for more than 50 years, dedicating his time and energy to advance Abcourt's projects. He participated in bringing the Elder mine into production and in the acquisition of the Sleeping Giant mining project and plant and the neighboring exploration properties, Discovery and Flordin, among others.
Abcourt's Management and Board of Directors wish to highlight the exceptional work of this pillar of the mining industry and offer their sincere condolences to the family and friends of Mr. Hinse.
ABOUT ABCOURT MINES INC.
Abcourt Mines Inc. is a Canadian exploration corporation with strategically located properties in northwestern Québec, Canada. Abcourt owns the Sleeping Giant mill and mine where it concentrates its activities.
For further information, please visit our website at www.abcourt.com and consult our filings under Abcourt's profile on www.sedar.com, or contact:
| Pascal HamelinPresident and CEOT: (819) 768-2857E: [email protected] | Dany Cenac Robert, Investor RelationsReseau ProMarket Inc.,T: (514) 722-2276, post 456E: [email protected] |
The TSX Venture Exchange and its regulatory service provider (as defined in the policies of the TSX Venture Exchange) assume no responsibility for the adequacy or accuracy of this press release.
Source: Abcourt Mines Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Chinese Bridge world final for secondary school students wraps up in Tianjin
- FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
- AS Tallinna Sadam operational volumes for 2026 Q3 and 9 months
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share